Gut–liver on a chip toward an in vitro model of hepatic steatosis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Hepatic steatosis is a process of abnormal lipid deposition within the liver cells, often caused by excessive alcohol uptake or obesity. A conventional in vitro model for hepatic steatosis uses a liver cell culture, treated with fatty acids and measures accumulation of lipids within the cells. This model does not recapitulate the complex process of absorption and metabolism of digestive lipids. Here, we introduce a gut–liver chip, which mimics the gut absorption and hepatic metabolism in a microfluidic chip. Absorption of fatty acids through gut layer and subsequent deposition within liver cells was demonstrated. Tumor necrosis factor‐α, butyrate, and α‐lipoic acid were chosen as model molecules that can affect hepatic steatosis via different mechanisms, and their effects were evaluated. Our results suggest that the gut–liver chip can mimic the absorption and accumulation of fatty acids in the gut and the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Peng, L., Li, Z.-R., Green, R. S., Holzmanr, I. R., & Lin, J. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.104638 · Cited by 2,130
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Engineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
Peng, L., He, Z., Chen, W., Holzman, I. R., & Lin, J. (2007) · Pediatric Research · doi:10.1203/01.pdr.0000250014.92242.f3 · Cited by 518 · cited 1×
“FITC‐dextran: fluorescein isothiocyanate‐dextran; TEER: trans‐epithelial electrical resistance; TNF‐α: tumor necrosis factor‐α increasing expression of tight junction proteins (Peng et al., 2007, 2009).”
BackgroundMa, T. Y., Boivin, M. A., Ye, D., Pedram, A., & Said, H. M. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00412.2004 · Cited by 452 · cited 1×
“It has been known that increased expression of TNF‐α results in compromising the gut barrier function by reduced expression of tight junction proteins (Ma et al., 2005; van der Bruggen, Nijenhuis, van Raaij, Verhoef, & van Asbeck, 1999).”
BackgroundMicrofluidic gut-on-a-chip with three-dimensional villi structure
Shim, K.-Y., Lee, D., Han, J., Nguyen, N.-T., Park, S., & Sung, J. H. (2017) · Biomedical Microdevices · doi:10.1007/s10544-017-0179-y · Cited by 229 · cited 7×
“In addition, the presence of local fluidic environment can also contribute to enhancement of physiological functions of cells (Shim et al., 2017).”
BackgroundMethodInfluentialSelf-citationWesterink, W. M. A., & Schoonen, W. G. E. J. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.06.017 · Cited by 226
van Midwoud, P. M., Merema, M. T., Verpoorte, E., & Groothuis, G. M. M. (2010) · Lab on a Chip · doi:10.1039/c0lc00043d · Cited by 203
Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow
Esch, M. B., Prot, J.-M., Wang, Y. I., Miller, P., Llamas-Vidales, J. R., Naughton, B. A., Applegate, D. R., & Shuler, M. L. (2015) · Lab on a Chip · doi:10.1039/c5lc00237k · Cited by 173
Cited by
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Recent Advances in Body-on-a-Chip Systems
Sung, J. H., Wang, Y. I., Narasimhan Sriram, N., Jackson, M., Long, C., Hickman, J. J., & Shuler, M. L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05293 · Cited by 268
Self-citationIn Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Liver-on-a-Chip models of fatty liver disease
Hassan, S., Sebastian, S., Maharjan, S., Lesha, A., Carpenter, A., Liu, X., Xie, X., Livermore, C., Zhang, Y. S., & Zarrinpar, A. (2020) · Hepatology · doi:10.1002/hep.31106 · Cited by 127
“Reprinted (A) with permission from Elsevier,(16) (B) and (D) from John Wiley & Sons,(17,18) respectively, (C) from IOP publishing,(19) and (E) from Royal Society of Chemistry.”
BackgroundMethodInfluentialIn Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
“also built a “gut-liver-on-a-chip” to study the gut–liver axis in the context of NAFLD [68].”
Background
Metadata
- Authors
- Lee, S. Y., & Sung, J. H.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2018-09-17
- Volume
- 115
- Issue
- 11
- Pages
- 2817-2827
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2866517222
- Cited by
- 111
- References
- 12
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.